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Van Loon, Luc J. C., Michaela Thomason-Hughes, Dumitru
Constantin-Teodosiu, Rene´ Koopman, Paul L. Greenhaff, D. Gra-
hame Hardie, Hans A. Keizer, Wim H. M. Saris, and Anton J. M.
Wagenmakers. Inhibition of adipose tissue lipolysis increases intra-
muscular lipid and glycogen use in vivo in humans. Am J Physiol
Endocrinol Metab 289: E482–E493, 2005. First published May 10,
2005; doi:10.1152/ajpendo.00092.2005.—This study investigates the
consequences of inhibition of adipose tissue lipolysis on skeletal muscle
substrate use. Ten subjects were studied at rest and during exercise and
subsequent recovery under normal, fasting conditions (control trial,
CON) and following administration of a nicotinic acid analog (low
plasma free fatty acid trial, LFA). Continuous [U-13C]palmitate and
[6,6-2H2]glucose infusions were applied to quantify plasma free fatty acid
(FFA) and glucose oxidation rates and to estimate intramuscular triacyl-
glycerol (IMTG) and glycogen use. Muscle biopsies were collected to
measure 1) fiber type-specific IMTG content; 2) allosteric regulators of
hormone-sensitive lipase (HSL), glycogen phosphorylase, and pyruvate
dehydrogenase; and 3) the phosphorylation status of HSL at Ser563 and
Ser565. Administration of a nicotinic acid analog (acipimox) substantially
reduced plasma FFA rate of appearance and subsequent plasma FFA
concentrations (P  0.0001). At rest, this substantially reduced plasma
FFA oxidation rates, which was compensated by an increase in the
estimated IMTG use (P  0.05). During exercise, the progressive
increase in FFA rate of appearance, uptake, and oxidation was prevented
in the LFA trial and matched by greater IMTG and glycogen use.
Differential phosphorylation of HSL or relief of its allosteric inhibition by
long-chain fatty acyl-CoA could not explain the increase in muscle TG
use, but there was evidence to support the contention that regulation may
reside at the level of the glucose-fatty acid cycle. This study confirms the
hypothesis that plasma FFA availability regulates both intramuscular
lipid and glycogen use in vivo in humans.
muscle metabolism; intramyocellular triacylglycerol; fat oxidation;
insulin resistance
ELEVATED PLASMA FREE FATTY ACID (FFA) concentrations are
associated with obesity and the development of insulin resis-
tance (38, 44). Combined with the fact that, in obese and/or
type 2 diabetes patients, skeletal muscle shows a reduced
capacity to oxidize FFA (20), this likely explains the increased
intramyocellular triacylglycerol (IMTG) storage in these sub-
jects (15, 27, 53). In agreement, various studies have reported
a strong relationship between elevated plasma FFA levels,
IMTG accretion, and insulin resistance (22, 32, 34). Insights
from various lipid infusion studies suggest that elevated plasma
FFA delivery and/or impaired fatty acid (FA) oxidation, result
in intramyocellular accumulation of triacylglycerol (TG) and
FA metabolites (such as fatty acyl-CoA, diacylglycerol, and
ceramides), which are likely to induce defects in the insulin-
signaling cascade, causing skeletal muscle insulin resistance
(1, 3, 16, 42, 65).
Insulin resistance can subsequently lead to the development
of the hyperglycemic and hyperinsulinemic state that is asso-
ciated with type 2 diabetes and accompanied by major distur-
bances in skeletal muscle substrate metabolism (17, 37). These
disturbances produce a state of metabolic inflexibility that
stimulates IMTG storage at the expense of its oxidation (20).
Recent data suggest that the structural imbalance between FFA
uptake and IMTG storage and its oxidation, and not the actual
size or distribution of the IMTG pool, is responsible for the
development of skeletal muscle insulin resistance (10, 48, 53).
It could be speculated that greater metabolic flexibility com-
bined with an elevated IMTG turnover rate would prevent
excessive accumulation of intramyocellular FA metabolites as
well as reduce the degree of lipid peroxidation (42) due to a
decreased resident time of the intramyocellular lipids. There-
fore, efforts should be made to develop interventions that
stimulate IMTG oxidation, which could be of great importance
in the prevention and/or treatment of skeletal muscle insulin
resistance (52). However, the latter is complicated, as infor-
mation on the regulation of IMTG metabolism is lacking (17).
Physical exercise stimulates IMTG use (23, 52, 54) and, as
such, represents an effective means to prevent and/or reduce
excess IMTG accretion. Recently, we (54) observed a progres-
sive decline in IMTG oxidation rate during prolonged moder-
ate-intensity exercise in healthy trained men. The latter was
inversely correlated with a concomitant increase in plasma
FFA concentration (54), supporting the contention that ele-
vated plasma FFA levels suppress IMTG oxidation during
exercise (40, 41, 54, 56). Consequently, we hypothesised that
plasma FFA concentrations regulate the balance between
IMTG storage and oxidation. With hormone-sensitive lipase
(HSL) (24) as the site at which IMTG mobilization and/or
oxidation is likely regulated, we speculated that HSL activity is
not only regulated by muscle contraction (25) and adrenalin
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(21, 26, 59), but may also be modified by changes in plasma
FFA availability. Indirect evidence for this is provided by the
in vitro observation that HSL is inhibited both by oleic acid and
oleoyl-CoA in adipose tissue (18). The presence of such a
feedback inhibition mechanism in muscle would serve to
protect against excessive intracellular accumulation of FA
(metabolites) during increased plasma FFA provision. If this
hypothesis is correct, reducing plasma FFA provision might
reduce intramyocellular FA (metabolite) concentrations, disin-
hibit HSL, and increase IMTG mobilization and oxidation at
rest and/or during prolonged exercise.
In the present study, contemporary stable isotope methodol-
ogy and fluoresence microscopy were applied to quantify
substrate source utilization at rest and during prolonged mod-
erate-intensity exercise under normal fasting conditions (con-
trol trial, CON) and following specific inhibition of adipose
tissue lipolysis, thereby reducing plasma FFA availability (low
FFA trial, LFA). In addition, we aimed to elucidate the mech-
anisms responsible for the anticipated shift in skeletal muscle
substrate use. We speculated that an acute reduction in plasma
FFA availability modulates skeletal muscle substrate use by
way of the Randle cycle, by activating AMP-activated protein
kinase (AMPK), by increasing acetyl-CoA carboxylase (ACC)
phosphorylation, and/or by stimulating muscle HSL by site-
specific phosphorylation (at Ser563 or Ser565). This study pro-
vides novel insight into the role of plasma FFA availability as
a main factor in modulating IMTG utilization and introduces
adipose tissue lipolytic inhibition as a practical intervention to
increase both intramuscular lipid and glycogen use at rest and
during exercise.
METHODS
Subjects. Ten fit, active male subjects [age 23  1 yr, height 1.82 
0.03 m, body wt 74  3 kg, fat-free mass 64  3 kg, maximal power
output (Wmax) 388  14 W, and maximal oxygen uptake capacity
(V˙ O2 max) 62  3 ml.kg body wt1.min1] were selected to participate
in this study. Subjects were informed about the nature and risks of the
experimental procedures before their written informed consent was
obtained. This study was approved by the local Medical Ethics
Committee.
Pretesting. Wmax and V˙ O2 max were measured on an electronically
braked cycle ergometer (Lode Excalibur, Groningen, The Nether-
lands) during an incremental exhaustive exercise test. Body compo-
sition was assessed using the hydrostatic weighing method in the
morning after an overnight fast. Body fat percentage was calculated
using Siri’s equation (46).
Diet and activity before testing. All subjects maintained normal
dietary and physical activity patterns throughout the experimental
period. In addition, they filled out a food intake diary for 2 days before
the first exercise trial to keep their dietary intake as identical as
possible before the other trials. The evening before each trial, subjects
received the same standardized meal (41.2 kJ/kg body wt, containing
72, 11, and 17% energy carbohydrate, fat, and protein, respectively).
Experimental trials. Each subject performed three trials separated
by at least a 1-wk interval. Each trial consisted of 90 min of resting
measurements, followed by 120 min of cycling exercise (50% Wmax)
and 120 min of recovery. In the two main trials, a [U-13C]palmitate
and a [6,6-2H2]glucose tracer were infused continuously at rest and
during exercise with breath, blood, and muscle samples collected at
regular intervals. In the LFA trial, plasma FFA availability was
reduced by oral administration of a peripheral lipolytic inhibitor (2
250 mg acipimox). In the CON trial, a placebo was provided. A third
trial was performed to determine the acetate recovery factor to correct
[U-13C]palmitate oxidation rates accurately for carbon label retention
in the bicarbonate pool(s) and by way of isotopic exchange reactions
in the TCA cycle (45).
Protocol. A schematic outline of the study protocol is provided in
Fig. 1. After an overnight fast, subjects arrived at the laboratory at
8:00 AM by car or public transportation. After 30 min of supine rest,
a percutaneous muscle biopsy was taken from the vastus lateralis
muscle. A Teflon catheter (Baxter, Utrecht, The Netherlands) was
inserted into an antecubital vein of one arm for blood sampling, and
another catheter was inserted in the contralateral arm for isotope
Fig. 1. Schematic outline of the study protocol. After initial blood, breath, and muscle biopsy sample, a continuous infusion with [U-13C]palmitate and
[6,6-2H2]glucose was started for 210 min. At rest and during exercise and postexercise recovery, whole body substrate use was studied under normal fasting
conditions (control trial, CON) and under reduced plasma free fatty acid (FFA) availability following administration of the nicotinic acid analog acipimox
(low-FFA trial, LFA).
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infusion. Thereafter, a resting blood sample was taken, and expired
breath samples were collected into Vacutainer tubes. Subsequently,
subjects were administered a single intravenous dose of NaH13CO3
(0.06375 mg/kg) to prime the bicarbonate pool(s), followed by a
[6,6-2H2]glucose prime (13.5 mol/kg). Thereafter, a continuous
infusion of [6,6-2H2]glucose (0.3 mol.kg1.min1) and [U-13C]
palmitate (0.01 mol.kg1.min1) (or [1,2-13C]acetate in the acetate
recovery trial) was started (t  0 min) via a calibrated IVAC pump
(IVAC 560, San Diego, CA) and continued for 210 min. At t  0 min
and t  165 min, a capsule containing 250 mg of acipimox (Nedios,
Byk, Zwanenburg, The Netherlands) or a placebo was orally admin-
istered. At t  90 min, subjects started to exercise on a cycle
ergometer at a workload of 50% Wmax for a 120-min period. While
subjects were at rest, V˙ O2 and V˙ CO2 were measured continuously
(Oxycon-, Mijnhart); during exercise V˙ O2 and V˙ CO2 were measured
for 5 min every 15 min before sampling of blood and expired breath.
Immediately after cessation of exercise, a second muscle biopsy was
taken, after which the subjects rested supine for 120 min during which
V˙ O2 and V˙ CO2 were again measured continuously. After 120 min of
postexercise recovery, a third muscle biopsy was taken. Breath and
blood samples were collected at t  0, 30, 60, 75, and 90 min (at rest)
and at t  105, 120, 135, 150, 165, 180, 195, and 210 min (during
exercise). In addition, blood samples were collected at t  225, 240,
270, 300, 315, and 330 min (during postexercise recovery).
Tracer infusion. Infusion rates of [U-13C]palmitate and [6,6-
2H2]glucose averaged 9.3  0.2 and 276.1  4.3 nmol kg1 min1,
respectively. At the onset of exercise [U-13C]palmitate infusion rates
were doubled (18.6  0.4 nmol kg1 min1). In the acetate recovery
trial, a corresponding amount of 13C was infused, resulting in an
average [1,2-13C]acetate infusion rate of 71.2  1.6 and 142.4  3.1
nmol kg1 min1 at rest and during exercise, respectively. Palmitate,
glucose, and acetate tracer concentrations in the infusates averaged
1.06  0.02, 21.3  0.6, and 4.64  0.10 mmol/l, respectively.
Blood and breath sample analysis. Blood samples (7 ml) were
collected in EDTA-containing tubes and centrifuged at 1,000 g for 10
min at 4°C. Aliquots of plasma were frozen immediately in liquid
nitrogen and stored at 80°C. Plasma glucose (Uni Kit III; Roche,
Basel, Switzerland), lactate (11), FFA (NEFA-C; Wako Chemicals,
Neuss, Germany), free glycerol (148270; Roche Diagnostics, India-
napolis, IN), and triglyceride (GPO-Trinder 337B; Sigma Diagnostics,
St Louis, MO) concentrations were analyzed with a COBAS semiau-
tomatic analyzer (Roche).
Expired-breath samples were analyzed for 13C/12C ratio by gas
chromatography-continuous flow isotope ratio mass spectrometry
(GC-IRMS; Finnigan MAT 252, Bremen, Germany). For determina-
tion of plasma palmitate and FFA kinetics, FFA were extracted from
plasma, isolated by thin-layer chromatography, and derivatized to
their methyl esters. Palmitate concentration was determined on an
analytic gas chromatograph with flame ionization detection using
heptadecanoic acid as an internal standard and on average comprised
22.9  1.0% of total FFA. Isotope tracer-to-tracee ratio (TTR) of
[U-13C]palmitate was determined using GC-combustion-IRMS
(Finnigan MAT 252). After derivatization, plasma [6,6-2H2]glucose
enrichment was determined by electron ionization GC-MS (Finnigan
INCOS-XL). Glucose (Uni Kit III, Roche) and acetate (Kit 148261,
Boehringer) concentrations in the infusates were determined with the
COBAS FARA.
Calculations. From respiratory measurements, total fat and carbo-
hydrate oxidation rates were calculated using the nonprotein respira-
tory quotient (33).
fat oxidation rate 1.695V˙ O2 1.701V˙ CO2 (1)
carbohydrate oxidation rate 4.585V˙ CO2 3.226V˙ O2 (2)
with V˙ O2 and V˙ CO2 in liters per minute and oxidation rates in grams
per minute. Breath and plasma enrichments are expressed as TTR:
TTR  13C/12C	sa 13C/12C	bk (3)
in which sa indicates sample and bk indicates background value. Rates
of palmitate and glucose appearance (Ra) and disappearance (Rd) were
calculated using the single-pool non-steady-state Steele equations
adapted for stable isotope methodology, as described elsewhere (63).
As such, plasma palmitate and glucose Rd were calculated by correct-
ing the Ra for the time-dependent changes in plasma metabolite
concentration.
Ra
F V
C2 C1	/2 
E2 E1	/t2 t1	
E2 E1	/2
(4)
Rd Ra V  C2 C1t2 t1  (5)
where F is the infusion rate (mol kg1 min1); V  distribution
volume for palmitate or glucose (40 and 160 ml/kg, respectively); C1
and C2 are the palmitate or glucose concentrations (mmol/l) at times
1 (t1) and 2 (t2), respectively, and E2 and E1 are the plasma palmitate
or glucose enrichments (TTR) at t1 and t2, respectively. 13CO2
production (Pr13CO2, mol/min) from the infused palmitate tracer was
calculated as
Pr13CO2 TTRco2  V˙ CO2	/k  Ar	 (6)
where TTRCO2 is the breath 13C/12C ratio at a given time point, V˙ CO2
is carbon dioxide production (l/min), k is the volume of 1 mol of CO2
(22.4 l/min), and Ar is the fractional 13C label recovery in breath CO2,
observed after the infusion of labeled acetate (45) and calculated as
Ar  TTRco2  V˙ CO2	/k  2F		 (7)
where F is infusion rate of [1,2-13C]acetate (mol/min). Plasma palmi-
tate oxidation (Rox, mol/min) can subsequently be calculated as
Rox palmitate Rd palmitate  Pr13CO2/F  16	 (8)
where Rd palmitate is the rate of palmitate disappearance (mol/min);
F is the palmitate infusion rate (mol/min), and 16 is the number of
carbon atoms in palmitate. Total plasma FFA oxidation was calculated
by dividing palmitate oxidation rates by the fractional contribution of
plasma palmitate to total plasma FFA concentration. Muscle-derived
TG use was estimated by subtracting plasma FFA oxidation from total
fat oxidation. However, it should be noted that the indirect stable
isotope methodology does not differentiate between muscle- or li-
poprotein-derived TG use. However, the contribution of lipoprotein-
derived TG oxidation to total energy expenditure is assumed to be of
relatively minor quantitative importance, especially in an overnight
fasted state (52).
In a previous study, where we applied both [U-13C]- and [6,6-
2H2]glucose tracers (19) during moderate intensity exercise, it was
shown that the percentage of plasma glucose Rd that was oxidized
varied between 96 and 100%. Therefore, plasma glucose oxidation
rate during exercise was calculated as
Rox plasma glucose Rd plasma glucose (9)
Muscle glycogen oxidation was calculated by subtracting plasma
glucose oxidation from total carbohydrate oxidation.
Muscle sample analyses. Muscle samples were freed from any
visible nonmuscle material and rapidly frozen in liquid nitrogen.
About 15 mg of each muscle sample were frozen in liquid nitrogen-
cooled isopentane and embedded in Tissue-Tek (Sakura Finetek,
Zoeterwoude, The Netherlands). Multiple serial sections (5 m) from
biopsy samples were thaw mounted together on uncoated, precleaned
glass slides for each subject and stained with Oil Red O together with
immunolabeled cellular constituents by use of the protocol described
before (53–55). The applied epifluorescence technique represents a
semiquantitative method that can be used to compare fiber type-
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specific intramyocellular lipid content between muscle cross sections
(53–55).
About 15–20 mg of each muscle biopsy sample were freeze-dried,
dissected free from visible blood and connective tissue, and pow-
dered. About 10 mg of muscle powder were then extracted with 0.5 M
perchloric acid containing 1 mM EDTA. After centrifugation, the
supernatant was neutralized with 2.2 M KHCO3 and used for deter-
mination of muscle phosphocreatine, free creatine (13), citrate (2),
lactate (13), glycogen, glucose 6-phosphate, free carnitine, acetylcar-
nitine, long-chain fatty acylcarnitine, long-chain fatty acyl-CoA,
CoASH, and acetyl-CoA (5) concentrations. Except for muscle lac-
tate, glycogen, and citrate, all these concentrations were corrected for
muscle total creatine content within each subject.
Another piece of muscle sample (20 mg) was ground to a fine
powder under liquid nitrogen and homogenized in 200 l of ice-cold
buffer, as described previously (8). For measurement of AMP-acti-
vated protein kinase (AMPK) activity, muscle lysates containing 100
g of protein were immunoprecipitated using 10 g of sheep anti-1-
plus 10 g of anti-2-AMPK coupled to protein G-Sepharose before
a standard AMPK assay was performed using AMARA-peptide
(AMARAASAAA-LARRR) as a substrate (12). HSL Ser563 and
Ser565 phosphorylation, acetyl-CoA carboxylase (ACC) Ser221 phos-
phorylation, and total ACC expression were measured in muscle
lysates containing 20 g of protein by SDS-PAGE followed by
Western blotting onto nitrocellulose (64). Membranes were probed
with affinity-purified antibodies as follows: anti-HSL phospho-Ser563
(0.2 g/ml), anti-HSL phospho-Ser565 (0.06 g/ml), anti-ACC phos-
pho-Ser221 (1 g/ml). Antibody binding was detected using the LiCor
Odyssey IR imaging system, which uses near-infrared (IR) fluorescent
dyes for detection of proteins. Briefly, membranes were incubated
with donkey anti-sheep IgG labeled with IRDye 680 (Molecular
Probes) for 1 h before being imaged. ACC expression was determined
using streptavidin labeled with IRDye 800 (Rockland Immuno-
chemicals). The sheep anti-1, anti-2, and phosphospecific ACC
antibodies have been described previously (14, 64). Sheep phos-
phospecific HSL antibodies against Ser565 and Ser563 were raised
against synthetic peptides CTESMRRSVSpEAALAQP and CT-
ESMRRSpVSEAALAQP, respectively (residues 556–571 of rat skel-
etal muscle HSL with cysteine at the NH2 terminus for coupling),
using methods previously described (47).
Statistics. All data are expressed as means  SE. To compare tracer
kinetics, substrate utilization rates, IMTG contents, and/or plasma
metabolite concentrations over time between trials, a two-way re-
peated-measures analysis of variance (ANOVA) was applied. Schef-
fe´’s post hoc test was applied in case of a significant F-ratio to locate
specific differences. For non-time-dependent variables, a Student’s
t-test for paired observations was used. Significance was set at the
0.05 level of confidence.
RESULTS
Tracer kinetics. Plasma FFA and glucose concentrations at
rest, exercise, and postexercise recovery under normal fasting
conditions (CON) and reduced plasma FFA availability (LFA)
are shown in Fig. 2. Because plasma concentrations varied over
time in the LFA and/or CON trial, non-steady-state Steele
equations were applied to calculate tracer kinetics. Plasma
glucose Ra and Rd were significantly higher during exercise
compared with resting values in both the CON and LFA trials
(Table 1), with Ra and Rd being increased over time during
exercise (Fig. 3A; P  0.001). No differences in plasma
glucose kinetics were observed between trials. In the CON
trial, plasma palmitate Ra, Rd, and Rox were significantly
higher during exercise compared with resting values (Table 1),
with Ra, Rd, and Rox being increased over time (Fig. 3B; P 
0.001). In the LFA trial, plasma palmitate Ra and Rd were
similar at rest and during exercise, with only Rox being signif-
icantly greater during exercise compared with resting values
(P  0.001; Table 1). No changes in plasma palmitate Ra, Rd,
and Rox were observed over time (Fig. 3B). Both at rest and
during exercise, plasma palmitate Ra, Rd, and Rox were sub-
stantially lower in the LFA trial than in the CON trial (P 
0.005; Table 1 and Fig. 3).
Plasma metabolite concentrations. Plasma FFA, glycerol,
TG, glucose, and lactate concentrations are shown in Fig. 2.
Plasma FFA concentrations in the CON trial increased
throughout the exercise period, reaching peak levels at 15 min
after cessation of exercise. Thereafter, plasma FFA concentra-
tions declined but remained well above preexercise resting
levels (P  0.0001). In contrast, plasma FFA concentrations in
the LFA trial decreased during exercise but increased gradually
toward preexercise levels during recovery (P  0.0001). At all
time points, plasma FFA concentrations were significantly
lower in the LFA than in the CON trial (P  0.001). Plasma
glycerol concentrations increased significantly during exercise
and decreased during postexercise recovery in both trials (P 
0.001). At all time points, free glycerol concentrations were
significantly lower in the LFA than in the CON trial (P 
0.0001). Plasma TG decreased gradually during exercise in
both trials (P  0.0001), with a tendency to increase during
recovery in the CON trial. Nevertheless, plasma TG levels
were not significantly different between trials. Plasma glucose
concentrations significantly declined during exercise in both
trials (P  0.0001), with no further changes during recovery.
Plasma lactate concentrations had increased well above preex-
ercise resting levels within the first 15 min of exercise, after
which plasma lactate concentrations declined throughout the
remaining experimental time in both trials (P  0.0001).
However, plasma lactate concentrations during recovery
were significantly greater in the LFA than in the CON trial
(P  0.05).
Substrate utilization. Energy expenditure and substrate
source utilization rates at rest are shown in Fig. 4A. Energy
expenditure was similar between trials and averaged 5.54 
0.23 and 5.26  0.24 kJ/min, respectively. However, substrate
source utilization significantly differed between trials (P 
0.05). Total fat oxidation rate averaged 0.09  0.01 and 0.07 
0.01 g/min, contributing 64  4 and 53  4% to energy
expenditure, in the CON and LFA trials, respectively (P 
0.01). The apparent difference in total fat oxidation was en-
tirely accounted for by a 38  7% reduction in plasma FFA
oxidation rate in the LFA compared with the CON trial (0.04 
0.004 and 0.07  0.006 g/min, respectively; P  0.01). In
contrast, estimated IMTG oxidation rates were substantially
augmented in the LFA compared with the CON trial (0.029 
0.005 vs. 0.017  0.006 g/min, respectively; P  0.05).
Carbohydrate oxidation rates were significantly higher in the
LFA compared with the CON trial, and averaged 0.15  0.01
and 0.12  0.02 g/min, respectively.
In the subsequent exercise trial, the applied 50% Wmax
workload averaged 194  7 W, corresponding to 59  1% of
V˙ O2 max. Energy expenditure and endogenous substrate source
utilization during exercise are illustrated in Figs. 4B and 5. In
the CON trial, total fat oxidation rate increased significantly
during exercise and was matched by a decrease in total carbo-
hydrate oxidation (P  0.001). The increase in total fat
oxidation rate during exercise in the CON trial, which occurred
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despite the progressive decline in IMTG- plus lipoprotein-
derived TG oxidation, was entirely accounted for by an in-
crease in plasma FFA oxidation rate (P  0.001; Fig. 5, A and
B). The decrease in total carbohydrate oxidation rate during
exercise in the CON trial was fully accounted for by the
gradual decrease in muscle glycogen use, whereas plasma
glucose oxidation rates significantly increased over time (P 
0.0001; Fig. 5, C and D). In contrast to the CON trial, total fat
Fig. 2. Plasma metabolite concentrations at
rest, during prolonged submaximal exercise,
and during 2 h of postexercise recovery in
CON and LFA trials. Data provided are
means  SE. *Significant increase over time
within resting, exercise, and/or postexercise
recovery period; ^significant decrease over
time within resting, exercise, and/or postex-
ercise recovery period (P  0.05).
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and carbohydrate oxidation rates remained stable during exer-
cise in the LFA trial. Total fat oxidation rates were signifi-
cantly lower in the LFA trial compared with the CON trial
(P  0.0001). This was entirely due to lower plasma FFA
oxidation rates in the LFA trial (P  0.0001; Fig. 5A).
Estimated IMTG oxidation rates remained stable throughout
exercise in the LFA trial and did not decline as shown in the
CON trial (P  0.0001). The latter resulted in significantly
greater muscle-derived TG use in the LFA compared with the
CON trial (Fig. 5B). Carbohydrate oxidation rates were sub-
stantially higher in the LFA compared with the CON trials
(P  0.001). Plasma glucose oxidation rates increased contin-
uously during exercise (P  0.0001) and were similar to those
observed in the CON trial (Fig. 5C). Therefore, the greater
carbohydrate oxidation rate in the LFA trial was entirely
attributed to the greater muscle glycogen use in the LFA trial
(Fig. 5D), which gradually declined during exercise similarly
to the observations in the CON trial (P  0.0001).
Average substrate source utilization, calculated over the
second hour of exercise, is illustrated in Fig. 4B. Total fat
oxidation averaged 0.61  0.04 and 0.39  0.03 g/min,
representing 43  4 and 28  2% of total energy expenditure
in the CON and LFA trials, respectively (P  0.001). In the
CON trial, plasma FFA oxidation provided 30  3% of total
energy expenditure, with muscle and plasma lipoprotein-de-
rived TG use contributing 13  1%. With low plasma FFA
availability in the LFA trial, plasma FFA oxidation was sub-
stantially impaired, providing only 9  1% of energy expen-
diture. In contrast, IMTG oxidation was significantly aug-
mented in the LFA trial, providing 19  2% of total energy
expenditure. Total carbohydrate oxidation rates averaged
1.98  0.13 and 2.54  0.10 g/min in the CON and LFA trials,
respectively (P  0.01). The greater carbohydrate oxidation
rate in the LFA trial was fully attributed to an increase in
muscle glycogen use (P  0.01), whereas plasma glucose
oxidation rates did not differ between trials.
Resting energy expenditure was significantly increased in
both trials during postexercise recovery compared with preex-
ercise values (6.1  0.3 and 5.7  0.2 kJ/min in the CON and
LFA trials, respectively). In the CON trial, this was entirely
attributed to a greater total fat oxidation rate compared with
preexercise resting values, with a concomitant decrease in
carbohydrate use (P  0.001). In the LFA trial, the higher
energy expenditure during recovery was fully accounted for by
a greater total carbohydrate oxidation rate. In line with preex-
ercise measurements, absolute as well as relative fat oxidation
rates were significantly higher in the CON trial compared with
the LFA trial during recovery (P  0.001).
Muscle tissue analysis. Muscle tissue analysis for IMTG
content using semiquantitative fluorescence microscopy on Oil
Red O-stained muscle cross sections showed a significant
decline in type I muscle fiber lipid content in both trials (P 
0.01; Fig. 6). The net decline in type I fiber lipid content was
Table 1. Tracer kinetics at rest and during exercise
Control Trial
(CON)
Low FFA Availability
(LFA)
Rest
Palmitate
Ra 2.340.22 1.410.15†
Rd 2.300.22 1.400.14†
Rox 0.810.09 0.450.06†
%Ra ox 34.31.78 31.31.81
Glucose
Ra 15.81.0 15.20.7
Rd 16.01.0 15.80.7
Exercise
Palmitate
Ra 5.280.57* 1.520.09†
Rd 5.230.56* 1.510.09†
Rox 4.800.48* 1.200.08*†
%Ra ox 92.03.04* 79.72.90*†
Glucose
Ra 31.81.8* 32.43.3*
Rd 33.01.9* 33.93.4*
Values are expressed as means  SE; n  8 subjects. Tracer kinetics as
calculated at rest and averaged during 2 h of exercise at 50% Wmax. Ra, rate of
appearance; Rd, rate of disappearance; Rox, rate of oxidation
(mol  kg1  min1); %Ra ox, %Ra palmitate oxidized. *Significantly different
from resting values (P  0.001); †significantly different between trials (P 
0.01).
Fig. 3. Plasma glucose rate of appearance
(Ra) and disappearance (Rd) (A) and plasma
palmitate Ra, Rd, and rate of oxidation (Rox)
(B) during prolonged submaximal endurance
exercise under normal fasting conditions
(CON) and following administration of a
peripheral lipolytic inhibitor (LFA) (in
mol  kg1  min1). Plasma glucose Ra and
Rd substantially increased during exercise in
both trials (P  0.0001). Plasma palmitate
Ra, Rd, and Rox significantly increased during
exercise in the CON trial (P  0.0001),
whereas in the LFA trial Ra, Rd, and Rox
remained stable over time at a substantially
lower value (P  0.0001). Data are means 
SE. *Significantly higher compared with val-
ues at t  30 min within each trial (P 
0.05); ^significant difference in Ra, Rd, and
Rox between trials (P  0.0001).
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significantly greater in the LFA group than in the CON group
(4.5  0.7 and 2.6  0.7% area lipid staining, respectively;
P  0.05). No changes in type II muscle fiber lipid content
were observed between trials. However, within the LFA trial,
type II fiber lipid content was significantly reduced after
exercise (P  0.05; Fig. 6B). The observed decreases in muscle
lipid content were attributed to a significant decrease in both
lipid droplet size and lipid droplet density (no. of droplets per
area; P  0.01). Mixed muscle metabolite concentrations, as
determined by biochemical analyses, are provided in Table 2.
Mixed muscle glycogen content decreased significantly in both
trials (P  0.01). The net difference between pre- and postex-
ercise values averaged 305  56 and 350  31 mmol/kg in the
CON and LFA trials, respectively (NS).
Skeletal muscle 2-AMPK activity averaged 0.025  0.005
and 0.025  0.007 (rest), 0.025  0.004 and 0.031  0.006
(postexercise), and 0.031  0.009 and 0.026  0.007 U/mg
(2-h recovery) in the CON and LFA trials, respectively. Total
AMPK activity averaged 0.049  0.009 and 0.040  0.005
(rest), 0.041  0.007 and 0.037  0.011 (postexercise), and
0.049  0.011 and 0.041  0.003 U/mg (2-h recovery),
respectively. No significant differences in 2-AMPK and/or
total AMPK activity were observed between the resting state,
end of exercise, and 2-h recovery within or between groups.
ACC phosphorylation status, expressed as the P-ACC/ACC
ratio, averaged 1.55  0.34 and 1.19  0.23 (rest), 1.78  0.51
and 2.12  0.66 (postexercise), and 1.75  0.51 and 1.45 
0.39 (2-h recovery) in the CON and LFA trials, respectively.
ACC phosphorylation status tended to be higher at the end of
exercise in the LFA trial (P  0.058), but no significant
differences were observed between trials. The phosphorylation
status of HSL at Ser563 did not change over time and averaged
3.46  0.55 and 2.97  0.52 (rest), 3.27  0.50 and 2.73 
0.53 (postexercise), and 3.98  0.80 and 2.65  0.62 (2-h
recovery) in the CON and LFA trials, respectively. Further-
more, HSL phosphorylation at Ser565 also did not change over
time and averaged 1.17  0.08 and 1.30  0.17 (rest), 0.99 
0.18 and 1.27  0.233 (postexercise), and 1.19  0.09 and
1.17  0.29 (2-h recovery), respectively. The phosphorylation
status of HSL at Ser563 or Ser565 did not differ between trials.
DISCUSSION
In the present study, acipimox administration is shown to
effectively inhibit in vivo peripheral lipolysis, with plasma
FFA Ra being substantially decreased at rest and during exer-
cise compared with normal, fasting conditions (Table 1 and
Figs. 2 and 3). The latter substantially reduced systemic FFA
availability, with plasma concentrations remaining well below
baseline level. As such, plasma FFA concentrations were
substantially reduced in the LFA vs. the CON trial (Fig. 2). The
reduction in FFA availability substantially increased the esti-
mated muscle TG use at rest (Fig. 4A). During exercise, the
absence of a progressive increase in plasma FFA availability in
the LFA trial was accompanied by muscle TG use being
sustained (Fig. 5), resulting in higher estimated muscle TG and
glycogen oxidation rates (Fig. 4B). In agreement with the tracer
data, a greater net decline in type I muscle fiber lipid content
was observed in the LFA vs. CON trial (Fig. 6). Although the
exact mechanisms responsible remain to be resolved, this study
provides definite evidence that plasma FFA availability regu-
lates muscle TG and glycogen use.
Nicotinic acid (analogs) has often been used to study the
effects of adipose tissue lipolytic inhibition on in vivo metab-
olism (43, 50, 51, 58). Nicotinic acid inhibits lipolysis by
binding to HM74 receptors in human adipose tissue (49).
Binding to these receptors results in a suppression of intracel-
lular cAMP levels, with a subsequent decrease in cAMP-
dependent protein kinase activity, leading to a reduced associ-
ation of HSL with its substrate in the lipid droplet of the
adipocyte (6). These antilipolytic properties are specific for
adipose tissue, as skeletal muscle does not express the HM74
receptor (49). Consequently, administration of nicotinic acid
analogs like acipimox can be used to specifically inhibit adi-
pose tissue lipolysis and reduce plasma FFA availability. In
accordance with that, following acipimox administration we
observed a massive reduction in plasma FFA Ra at rest and
Fig. 4. Whole body substrate source utilization (in kJ/min) at rest (A) and
during the 2nd h of exercise (B) in CON and LFA trials. *Significant difference
in plasma FFA, other fat sources, total carbohydrate, and/or plasma glucose
Rox between trials (P  0.05).
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during exercise and subsequent recovery (Table 1), with FFA
levels remaining well below baseline level (Fig. 2).
There has been much debate on the role of the IMTG pool
as a substrate source at rest and/or during exercise (52, 57).
Recently, we demonstrated that, besides plasma FFA, muscle-
derived TG provides a substantial contribution to energy ex-
penditure during exercise in trained males (54). In agreement,
we demonstrated a 60% net decline in type I muscle fiber
lipid content in vastus lateralis muscle following 120 min of
exercise (54). Furthermore, we observed a strong, progressive
decline in the oxidation rate of muscle (plus lipoprotein)-
derived TG use during exercise. The latter correlated with the
concomitant increase in plasma FFA Ra and oxidation (54).
Those findings confirmed earlier estimations (40, 41) as well as
more recent observations (56) and support the contention that
the progressive increase in peripheral lipolytic rate and the
subsequent increase in plasma FFA availability suppress IMTG
mobilization and/or oxidation. In agreement, Watt et al. (58)
recently reported a greater net decline in mixed muscle TG
content following nicotinic acid administration in a 3-h exer-
cise trial. In the present study, we extended their findings by
investigating whether inhibition of adipose tissue lipolysis
could stimulate IMTG use at rest and/or prevent the progres-
sive decline in IMTG utilization rate in time during exercise,
resulting in a greater net decline in fiber type-specific IMTG
content.
At rest, the threefold lower plasma FFA availability in the
LFA trial (Fig. 2) strongly reduced plasma FFA oxidation rates
(Table 1). The latter was compensated by a significant increase
in the use of other fat sources as well as higher carbohydrate
oxidation rates (Fig. 4A). These other fat sources are generally
assumed to reflect the use of muscle-derived TG. However, the
applied stable isotope methodology does not allow differenti-
ation between muscle- and lipoprotein-derived TG use. Al-
though the contribution of lipoprotein-derived TG oxidation to
total energy turnover is generally assumed to be of little
quantitative importance in an overnight-fasted state (52), it
should be noted that specific tissues likely contribute more
substantially to the use of lipoprotein-derived TG. Further-
more, plasma lipoprotein-derived TG use may likely be in-
creased during exercise conditions. Our data imply that, during
resting conditions, IMTG turnover is augmented when plasma
FFA availability is reduced. As we applied a [6,6-2H2]glucose
tracer, plasma glucose oxidation rates could not be quantified
at rest. The latter is due to the fact that, in contrast to exercise
conditions, glucose Rd does not match Rox during resting
conditions (19). However, plasma glucose Ra (hepatic glucose
output) and Rd (whole body glucose uptake) were not affected
by these short-term alterations in plasma FFA availability. The
latter is in accord with previous reports on acipimox adminis-
tration, which reported no change in plasma glucose Rd under
basal resting conditions (43, 50).
Fig. 5. Plasma FFA (A), other fat sources
(B), plasma glucose (C), and muscle glyco-
gen (D) Rox over time during prolonged
moderate-intensity exercise in CON and
LFA trials. Data are means  SE. *Signifi-
cantly different between trials (P  0.05).
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During exercise, we observed a progressive increase in total
fat Rox and a concomitant reduction in carbohydrate use under
normal fasting conditions (CON). The greater fat Rox was fully
accounted for by a progressive increase in plasma FFA Ra, Rd,
and Rox and was accompanied by a decline in the use of muscle
(and lipoprotein)-derived TG (Table 1 and Figs. 4 and 5). The
latter is in agreement with others’ (40, 41, 56, 58) as well as
our recent observations (54), showing a progressive decline in
IMTG use during prolonged moderate-intensity exercise under
fasting conditions in healthy men. In the present study, acipi-
mox administration effectively inhibited adipose tissue lipoly-
sis, thereby preventing the exercise-induced increase in plasma
FFA Ra, Rd, and Rox (Figs. 2 and 3). Consequently, no changes
in substrate source utilization were observed throughout exer-
cise in the LFA trial. As such, estimated IMTG Rox did not
decline but remained elevated throughout the entire exercise
trial (Fig. 5B). This led to substantially greater estimated IMTG
utilization rates during the latter stages of prolonged exercise in
the LFA trial (Figs. 4 and 5). In agreement with the isotope
tracer data, a greater net decline in type I muscle fiber lipid
content was observed in the LFA trial (Fig. 6). Similar to the
resting data, plasma glucose disposal during exercise was not
affected by the acute changes in FFA availability (Table 1 and
Figs. 3–5). As such, the higher carbohydrate Rox in the LFA
trial was entirely attributed to increased muscle glycogen use
(Figs. 4 and 5). However, net changes in mixed muscle gly-
cogen content in the biopsy samples did not significantly differ
between trials and averaged 350  31 and 305  56 mmol/kg
in the LFA and CON trials, respectively (Table 2).
Our second aim was to elucidate the mechanisms responsi-
ble for the shift in substrate use. We speculated that a reduction
in plasma FFA availability stimulates carbohydrate use via the
Randle cycle (36). A reduction in FFA availability could
stimulate muscle glycogen use by stimulating pyruvate dehy-
drogenase complex (PDC) activation (via a reduction in the
mitochondrial acetyl-CoA/CoASH ratio) and increasing glyco-
lytic flux (via a lower citrate concentration, thereby disinhib-
iting phosphofructokinase). Furthermore, the higher glycolytic
flux would lead to a greater decrease in glucose 6-phosphate
concentration, which would relieve its inhibition on glycogen
phosphorylase and hexokinase activity. The latter would ac-
celerate muscle glycogenolysis and/or upregulate plasma glu-
cose uptake, respectively. Some evidence to support this con-
tention was observed, as muscle samples obtained after exer-
cise showed significantly lower ratios of acetyl-CoA/CoASH
and acetylcarnitine/carnitine in the LFA vs. CON trial (Table
2). Furthermore, skeletal muscle citrate and glucose 6-phos-
phate levels tended to be lower in the LFA trial. Whereas
estimated muscle glycogen use was indeed elevated in the LFA
trial, plasma glucose uptake did not differ between trials.
The greater IMTG use during exercise in the LFA trial was
entirely attributed to the absence of the progressive decline in
IMTG use, as was observed in the CON trial (Fig. 5B).
Fig. 6. Fiber type-specific intramyocellular lipid content (expressed as
%area lipid stained) before exercise, immediately after exercise, and after
2 h of postexercise recovery as determined in type I (A) or type II (B)
muscle fibers by use of semiquantitative fluoresence microscopy on Oil Red
O-stained muscle cross sections. Data provided are means  SE. *Signif-
icantly lower vs. preexercise values; ‡significantly lower vs. type I muscle
fibers (P  0.05).
Table 2. Muscle metabolites
Control Trial (CON) Low FFA Availability Trial (LFA)
Preexercise Postexercise Recovery Preexercise Postexercise Recovery
Free carnitine, mmol/kg 16.661.20 9.351.08* 13.531.71 17.290.57 13.120.69*† 17.460.75‡†
Acetylcarnitine, mmol/kg 4.010.72 11.231.06* 7.251.19‡ 3.240.38 7.580.66*† 3.350.48‡†
LC-fatty acylcarnitine, mmol/kg 1.250.11 1.400.08 1.400.10 1.330.06 1.530.10 1.490.11
CoASH, mol/kg 104.77.9 76.48.8* 77.57.0* 97.46.9 92.55.0 103.87.4†
LC-fatty acyl-CoA, mol/kg 10.431.37 7.341.53 7.411.51 6.061.04† 6.000.76 5.050.82
Acetyl-CoA, mol/kg 15.782.21 34.345.40 27.516.08* 17.831.90 23.702.13 14.592.29‡
Acetyl-CoA/CoASH 0.150.02 0.500.09* 0.400.09 0.190.02 0.260.02† 0.150.03‡
Citrate, mmol/kg 1.150.09 2.120.29* 1.550.43‡ 1.150.14 1.480.13 1.200.15
Glucose 6-phosphate, mmol/kg 2.580.59 1.860.37 1.690.32 3.921.06 1.440.46 2.920.93
Glycogen, mmol/kg 58650 28125* 29036* 59538 24543* 26843*
Lactate, mmol/kg 3.100.71 9.152.82 4.762.02 3.870.69 7.373.03 5.441.66
Values are means  SE; n  10. Intramuscular free carnitine, acetylcarnitine, long-chain (LC) fatty acylcarnitine, CoASH, LC-fatty acyl-CoA, acetyl-CoA,
citrate, glucose 6-phosphate (p), glycogen, and lactate concentrations (expressed per kg dry muscle wt) before and after exercise and after 2 h of postexercise
recovery in CON and LFA. Except for citrate concentrations, all concentrations have been normalized to total muscle creatine content. *Significantly different
from resting values within each trial (P  0.05); †significantly different between trials (P  0.05); ‡significantly different from postexercise values within each
trial.
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Because muscle TG mobilization by HSL (24) represents the
rate-limiting step in IMTG lipolysis, we investigated which
mechanism(s) could be responsible for the increased activation
of HSL in the LFA trial. We speculated that the reduced
availability of plasma FFA could affect AMPK activation and
the phosphorylation status of HSL at Ser565. Furthermore,
previous studies (58) have reported a greater increase in plasma
epinephrine concentrations during exercise after nicotinic acid
administration, which could stimulate HSL activation by the
phosphorylation of HSL at Ser563, acting through PKA. In
addition, long-chain fatty acyl-CoA concentrations have been
shown to inhibit HSL allosterically in adipose tissue (24) and
muscle homogenates (24). A lower plasma FFA availability
could reduce intramuscular long-chain fatty acyl-CoA concen-
trations and reduce allosteric inhibition of HSL. Despite our
efforts to unravel the mechanism(s) responsible for the greater
IMTG use in the LFA trial, we could not find evidence to
support any of these mechanisms. Neither AMPK and 2-
AMPK activity nor ACC phosphorylation status changed from
rest to exercise and were not elevated after cessation of
exercise in the LFA trial. These findings are in accord with
Watt et al. (58), who also reported a greater net decline in
mixed muscle lipid content following exercise when nicotinic
acid was administered. In accord with the absence of changes
in AMPK activity, no significant changes were observed in the
phosphorylation status of ACC and the phosphorylation status
of HSL at either Ser563 or Ser565. The latter findings are in line
with recent observations by Roepstorff et al. (39) showing no
changes in HSL phosphorylation at either Ser563 or Ser565 after
60 min of moderate-intensity exercise under normal (non-
glycogen-depleted) conditions despite a substantial increase in
plasma epinephrine concentration. Furthermore, we did not
observe a greater decline in intramuscular fatty acyl-CoA
concentrations in the LFA trial (Table 2). The latter does not
necessarily prove that reduced long-chain acyl-CoA concen-
trations are not responsible for the greater IMTG use under
reduced plasma FFA availability, as compartmentalization of
the long-chain fatty acyl-CoA pool has been suggested to occur
(18). Consequently, although we clearly show that reduced
plasma FFA availability stimulates IMTG use in vivo, the
exact mechanism responsible remains to be elucidated.
The present study shows that inhibition of adipose tissue
lipolysis using a nicotinic acid analog elevates intramuscular
lipid and glycogen use. These findings could be of clinical
relevance for the prevention and/or treatment of skeletal mus-
cle insulin resistance. Depletion of both intramuscular lipid and
glycogen content are associated with the exercise-induced
increase in skeletal muscle insulin sensitivity (52, 62). In
agreement, interventions known to improve insulin sensitivity,
like dietary lipid withdrawal (30), acute exercise (30, 54), and
the use of thiazolidinediones (31) have all been associated with
a concomitant reduction in IMTG content. Peroxisome prolif-
erator-activated receptor- (PPAR) agonists, like the thiazo-
lidinediones, improve insulin sensitivity partly through lipid
retention in adipose tissue, thereby stimulating the redistribu-
tion of TG from skeletal muscle and liver back to adipose
tissue (28). Nicotinic acid (analogs) seems to act along the
same paradigm. Similar to the metabolic consequences of
excess muscle lipid accretion, increased muscle glycogen stor-
age following overfeeding and/or inactivity has been reported
to induce insulin resistance (29). In reverse, exercise stimulates
muscle glycogen use (23) and augments insulin sensitivity,
even in an insulin-resistant state (35, 61). The depletion of the
muscle glycogen stores is associated with this exercise-induced
increase in insulin sensitivity (35, 61), which can be main-
tained for up to 48 h (60) depending on the rate of muscle
glycogen repletion (7, 9). Consequently, combined exercise
and pharmacological interventions that elevate intramuscular
lipid and/or glycogen use are likely more effective to maximize
the exercise-induced increase in insulin sensitivity. The latter
could be even more relevant in an insulin-resistant state, in
which intramuscular lipid (52) and glycogen (4) use seem to be
impaired.
In conclusion, oral administration of a nicotinic acid analog
effectively suppresses adipose tissue lipolysis both at rest
and during exercise conditions. The subsequent reduction in
plasma FFA availability stimulates intramuscular lipid
oxidation both at rest and during exercise. Inhibition of adi-
pose tissue lipolysis during exercise provides an effective
mechanistic approach to increase intramuscular lipid and
glycogen use.
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